DK2305656T3 - Optiske isomerer of en iloperidonmetabolit - Google Patents

Optiske isomerer of en iloperidonmetabolit

Info

Publication number
DK2305656T3
DK2305656T3 DK10009915.9T DK10009915T DK2305656T3 DK 2305656 T3 DK2305656 T3 DK 2305656T3 DK 10009915 T DK10009915 T DK 10009915T DK 2305656 T3 DK2305656 T3 DK 2305656T3
Authority
DK
Denmark
Prior art keywords
optical isomers
iloperidone metabolite
fouoro
isoxazol
piperidin
Prior art date
Application number
DK10009915.9T
Other languages
Danish (da)
English (en)
Inventor
Hans O Kalkman
Hequn Yin
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2305656T3 publication Critical patent/DK2305656T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10009915.9T 2001-08-31 2002-08-30 Optiske isomerer of en iloperidonmetabolit DK2305656T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
EP02767454A EP1425272B1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
DK2305656T3 true DK2305656T3 (da) 2013-02-11

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10009915.9T DK2305656T3 (da) 2001-08-31 2002-08-30 Optiske isomerer of en iloperidonmetabolit
DK02767454.8T DK1425272T3 (da) 2001-08-31 2002-08-30 Optiske isomerer af en iloperidon-metabolit

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02767454.8T DK1425272T3 (da) 2001-08-31 2002-08-30 Optiske isomerer af en iloperidon-metabolit

Country Status (9)

Country Link
US (4) US20050020632A1 (enExample)
EP (2) EP1425272B1 (enExample)
JP (6) JP2005504783A (enExample)
AT (1) ATE518845T1 (enExample)
CY (2) CY1112039T1 (enExample)
DK (2) DK2305656T3 (enExample)
ES (2) ES2398434T3 (enExample)
PT (2) PT2305656E (enExample)
WO (1) WO2003020707A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441727B1 (en) 2001-10-30 2010-12-29 Novartis AG Depot formulations of iloperidone and a star polymer
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA2582022C (en) * 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
KR20090029200A (ko) * 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
JP5586094B2 (ja) 2007-03-29 2014-09-10 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
EP3075865B1 (en) 2007-05-18 2018-05-09 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2009036100A2 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of qt prolongation based on snp genotype
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
CA2709103C (en) 2007-12-13 2017-01-17 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
AU2008334933B2 (en) 2007-12-13 2016-01-21 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
WO2010117943A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
WO2010117937A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation
EP2417267B1 (en) 2009-04-06 2016-08-17 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
EP2416778B1 (en) 2009-04-06 2016-03-02 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
BR112014022687A8 (pt) * 2012-03-14 2021-07-06 Vanda Pharmaceuticals Inc uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo
EP3258935B1 (en) 2015-02-17 2021-04-07 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
US11773118B2 (en) 2019-02-21 2023-10-03 Obi Pharma, Inc. Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
EP4507698A1 (en) 2022-04-13 2025-02-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
IL321015A (en) 2022-12-19 2025-07-01 Vanda Pharmaceuticals Inc ILOPERIDONE dosing regimen for the treatment of bipolar I disorder and schizophrenia
CN121218989A (zh) 2023-06-02 2025-12-26 万达制药公司 使用伊潘立酮的治疗方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
EP0402644B1 (en) * 1989-05-19 1995-08-16 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU735249B2 (en) * 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.

Also Published As

Publication number Publication date
EP2305656B1 (en) 2012-10-24
EP2305656A1 (en) 2011-04-06
US20050020632A1 (en) 2005-01-27
US20130296366A1 (en) 2013-11-07
HK1156309A1 (en) 2012-09-07
US7977356B2 (en) 2011-07-12
CY1112039T1 (el) 2015-11-04
ES2398434T3 (es) 2013-03-19
PT1425272E (pt) 2011-10-19
EP1425272B1 (en) 2011-08-03
WO2003020707A1 (en) 2003-03-13
JP2013227335A (ja) 2013-11-07
US8314129B2 (en) 2012-11-20
JP2010100633A (ja) 2010-05-06
JP2005504783A (ja) 2005-02-17
ES2370634T3 (es) 2011-12-21
US20110201646A1 (en) 2011-08-18
US20090176739A1 (en) 2009-07-09
EP1425272A1 (en) 2004-06-09
DK1425272T3 (da) 2011-11-21
JP2015227368A (ja) 2015-12-17
ES2398434T8 (es) 2017-10-09
PT2305656E (pt) 2013-01-10
HK1066536A1 (en) 2005-03-24
JP2015214577A (ja) 2015-12-03
ATE518845T1 (de) 2011-08-15
JP2013116905A (ja) 2013-06-13
CY1113550T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
DK2305656T3 (da) Optiske isomerer of en iloperidonmetabolit
DE502004009532D1 (de) Fungizide ternäre wirkstoffkombinationen
NO20071193L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
NO20073366L (no) 1,6-substituert (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-2,5-piperazindionderivater som oksytocinreceptorantagonister for behandling av for tidlige veer, dysmenorri og endometriose
HRP20110640T1 (hr) Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
JP2008513405A5 (enExample)
JP2013510155A5 (enExample)
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
WO2007066163A3 (en) Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
EA200401290A1 (ru) НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa
UY31400A1 (es) Composiciones farmaceuticas
SE0102809D0 (sv) Novel compounds
DE602006010329D1 (de) Verfahren zur herstellung eines indolon-derivats
DK4178548T3 (da) Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
NO20056188L (no) Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes
HN2005000205A (es) Compuestos terapeuticos
AR026673A1 (es) Benzoilpirazoles sustituidos por 3-(4,5-dihidroisoxazol-3-ilo)
ATE311394T1 (de) Benzoesäureester mit antiplasmideffekt